SIK1B

Across TCGA pan-cancer cohorts, SIK1B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SIK1B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SIK1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIK1B expression acts as an unfavorable survival marker.

LUAD are the cancer types where SIK1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.369	1.000	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SIK1B–LUAD (OS)

Open the LUAD breakdown →